REG - Spectral MD Holdings - Block Listing Six Monthly Return

Spectral MD HoldingsAnnouncement

01/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230601:nRSA2557Ba&default-theme=true

RNS Number : 2557B  Spectral MD Holdings, Ltd.  01 June 2023

 

Spectral MD Holdings, Ltd

        ("Spectral MD" or the
"Company")

 

Block Listing Six Monthly Return

 

LONDON, U.K. AND DALLAS, TX, U.S -Spectral MD Holdings, Ltd. (AIM: SMD), an
artificial intelligence (AI) company focused on medical diagnostics for faster
and more accurate treatment decisions in wound care, provides the following
information in connection with its block admissions pursuant to AIM Rule 29
and Schedule Six of the AIM Rules for Companies:

 

 Name of applicant:                                                                  Spectral MD Holdings, Ltd.
 Name of scheme:                                                                     2018 Long-Term Incentive Plan
 Period of return:                         From:                                     8 November 2022  To:         7 May 2023
 Balance of unallotted securities under scheme(s) from previous return:              2,000,000 Ordinary shares
 Plus:  The amount by which the block scheme(s) has been increased since the         -
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:          104,451 Ordinary shares
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:          1,895,549 Ordinary shares

 

 Name of contact:              Vince Capone, General Counsel/Corporate Secretary
 Telephone number of contact:  +1 972 499-4934

 

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.
 Wensheng Fan, Chief Executive Officer                    IR@Spectralmd.com

 Nils Windler, Chief Financial Officer                    via Walbrook PR

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker for Spectral MD)
 Stuart Gledhill / Harry Davies-Ball (Corporate Finance)  Tel: +44 (0)20 3470 0470

 Vadim Alexandre / Rob Rees (Sales & Broking)

 The Equity Group Inc. (US Investor Relations)
 Devin Sullivan                                           dsullivan@equityny.com

                                                          Tel: 212-836-9608

 Walbrook PR Ltd (UK Media & Investor Relations)
 Paul McManus / Louis Ashe-Jepson /Alice Woodings         spectralMD@walbrookpr.com

                                                          Tel: +44 (0)20 7933 8780

About Spectral MD

Spectral MD is a predictive AI company focused on medical diagnostics for
faster and more accurate treatment decisions in wound care for burn, DFU, and
future clinical applications. At Spectral MD, we are a dedicated team of
forward-thinkers striving to revolutionize the management of wound care by
"Seeing the Unknown"® with our DeepView® Wound Diagnostics System. The
Company's DeepView® platform is the only predictive diagnostic device that
offers clinicians an objective and immediate assessment of a wound's healing
potential prior to treatment or other medical intervention. With
algorithm-driven results that substantially exceed the current standard of
care, Spectral MD's diagnostic platform is expected to provide faster and more
accurate treatment insight, significantly improving patient care and clinical
outcomes. For more information, visit the Company at: www.spectralmd.com
(http://www.spectralmd.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRNKDBBCBKDPPN